Avivia

Executive Summary

Avivia is a Netherlands-based pharmaceutical contract research organization (CRO) founded in 2017, specializing in formulation development, analytical testing, and excipient analysis. The company offers integrated services that bridge the gap from API to finished pharmaceutical formulations, positioning itself as a CMO-independent partner. Operating in the competitive CRO/CDMO landscape, Avivia focuses on drug repositioning and reformulation, providing value to sponsors seeking flexible, small-scale development support. Despite limited public information, Avivia's niche in formulation and analytical services, combined with its location in the European pharmaceutical hub of Amsterdam, suggests potential for steady growth. However, as a private company with no disclosed funding or commercial products, its near-term outlook is uncertain and heavily dependent on client project wins and market differentiation.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Biotech or Pharma Company40% success
• TBDExpansion of Analytical Testing Capabilities or New Service Offering50% success
• TBDAnnouncement of a Lead Customer or Development Contract60% success